Maximum number of tokens in answers: 705
Average number of tokens in answers: 65.23004081632654
Evaluation Model Used: gpt-5
Number of Prompts Printed: 5
Number of Prompts Used for Calculating the Average for Each Metric: 20 

================================================================================
Prompt: [INST] <<SYS>>
You are a helpful AI assistant that answers biomedical research questions concisely.
<</SYS>>
Context:
To assess whether experts can provide high-quality answers to occupational safety and health (OSH) questions in online Question&Answer (Q&A) networks. The authors evaluated the quality of answers provided by qualified experts in two Dutch online networks: ArboAntwoord and the Helpdesk of the Netherlands Center for Occupational Diseases. A random sample of 594 answers was independently evaluated by two raters using nine answer quality criteria. An additional criterion, the agreement of answers with the best available evidence, was explored by peer review of a sample of 42 answers. Reviewers performed an evidence search in Medline. The median answer quality score of ArboAntwoord (N=295) and the Netherlands Center for Occupational Diseases Helpdesk (N=299) was 8 of 9 (IQR 2). The inter-rater reliability of the first nine quality criteria was high (κ 0.82-0.90, p<0.05). A question answered by two or more experts had a greater probability of a high-quality score than questions answered by one expert (OR 4.9, 95% CI 2.7 to 9.0). Answers most often scored insufficient on the use of evidence to underpin the answer (36% and 38% for the networks, respectively) and on conciseness (35% and 31%, respectively). Peer review demonstrated that 43%-72% of the answers in both online networks were in complete agreement with the best available evidence.
Question:
Can online networks provide quality answers to questions about occupational safety and health?
[/INST]

Generated Answer: Yes, online networks can provide quality answers to questions about occupational safety and health. The study you mentioned evaluated the quality of answers provided by qualified experts in two Dutch online networks, ArboAntwoord and the Netherlands Center for Occupational Diseases Helpdesk, and found that the median answer quality score was 8 out of 9, indicating a high level of quality. The inter-rater reliability of the first nine quality criteria was also high, indicating that the raters were consistent in their evaluation. Additionally, the study found that answers provided by two or more experts were more likely to have a high-quality score than answers provided by one expert. However, there were some areas for improvement, such as the use of evidence to underpin the answers and the conciseness of the answers. Peer review demonstrated that a significant proportion of the answers were in complete agreement with the best available evidence. Overall, the study suggests that online networks can be a valuable resource for accessing high-quality information on occupational safety and health.

Provided Answer: OSH experts are able to provide quality answers in online OSH Q&A networks. Our answer quality appraisal instrument was feasible and provided information on how to improve answer quality. 

correctness: 0.9
Reasoning:
The answer correctly addresses the question by concluding that online OSH networks can provide high-quality answers and supports this with key findings from the study: high median quality (8/9), strong inter-rater reliability, improved quality with multiple expert responders, and identified areas for improvement (use of evidence and conciseness). It is accurate and aligned with the provided context. Minor improvements could include stating the exact peer-review agreement range (43%–72%) and specific insufficiency rates.

conciseness: 0.9
Reasoning:
The response begins with a clear “Yes” and stays focused on the study’s findings, citing key metrics (median 8/9 quality score, high inter-rater reliability, multi-expert advantage, areas for improvement, and evidence agreement). It is concise while still providing essential data to substantiate the claim. It could be slightly shorter by trimming repeated phrasing, but overall it is to the point.

relevance: 1.0
Reasoning:
The assistant’s response directly answers the question (“Yes”) and supports it with specific details from the provided context, including the median quality score (8/9), high inter-rater reliability (κ 0.82–0.90), higher quality with multiple experts (OR 4.9), common shortcomings (evidence use and conciseness), and peer-review agreement with evidence (43%–72%). These references accurately reflect the context and are relevant to the question. Overall, the response is well-aligned with the ground truth.

coherence: 0.9
Reasoning:
The response is coherent and well-structured. It directly answers the question with a clear “Yes,” and supports this with key findings from the study (high median quality score, strong inter-rater reliability, higher quality with multiple experts). It also notes areas for improvement (evidence use and conciseness) and references peer review agreement, though it could be slightly improved by providing the exact percentages (43–72%) and being a bit more concise. Overall, it aligns well with the provided context.

helpfulness: 0.9
Reasoning:
The response directly answers the question and accurately summarizes key findings from the provided context: high median quality scores (8/9), strong inter-rater reliability, improved quality with multiple experts, and noted areas for improvement (evidence use and conciseness). It appropriately concludes that online networks can provide quality OSH answers. Minor improvements could include citing specific percentages for evidence agreement (43–72%) and deficiencies, but overall it is concise and helpful.

================================================================================
================================================================================
Prompt: [INST] <<SYS>>
You are a helpful AI assistant that answers biomedical research questions concisely.
<</SYS>>
Context:
Fecal immunochemical tests (FIT) are preferred over guaiac-based fecal occult blood testing as colorectal cancer (CRC) screening tool. However, hemoglobin (Hb) degradation over time may influence FIT outcome. We therefore evaluated the effect of sample return time on FIT performance characteristics in a population-based CRC screening trial. A representative random sample of the Dutch population (n=17,677), aged 50-74 years, was invited for FIT screening (OC-Sensor Micro; cutoff ≥ 50 ng Hb/ml). Sample return time was defined as the interval in days between fecal sampling and FIT laboratory delivery. Moreover, a random sample of positive FITs were selected to be stored at room temperature and re-tested every 3-4 days. In total, 8,958 screenees fulfilled our inclusion criteria. The mean sample return time was 3 days (± 3). Overall, 792 screenees (8.8%) had a positive test. Between the sample return time groups, the positivity rate (PR) varied between 7.7 and 9.0%. No statistically significant associations were found between PR or detection rate (DR) and the different sample return time groups (P value=0.84 and 0.76, respectively). For the laboratory experiment, 71 positive FITs were stored at room temperature and re-tested with standard intervals. The mean daily fecal Hb decrease was 5.88% per day (95% confidence interval 4.78-6.96%). None of the positive FITs became negative before 10 days after fecal sampling.
Question:
Are fecal immunochemical test characteristics influenced by sample return time?
[/INST]

Generated Answer: Yes, the characteristics of fecal immunochemical tests (FITs) are influenced by sample return time. The study found that the positivity rate (PR) and detection rate (DR) of FITs varied between different sample return time groups, although the differences were not statistically significant. Specifically, the PR ranged from 7.7% to 9.0% and the DR ranged from 75.6% to 81.7% across the different sample return time groups. These findings suggest that the time interval between fecal sampling and FIT laboratory delivery can impact the accuracy of FIT results.

It is important to note that the study did not find any statistically significant associations between PR or DR and the different sample return time groups, which may be due to the relatively short sample return time intervals used in the study (range: 3-4 days). However, the study did observe a trend towards lower PR and DR with longer sample return times, suggesting that longer sample return times may result in lower FIT accuracy.

The study also conducted a laboratory experiment to investigate the effect of sample return time on FIT performance. The results showed that fecal hemoglobin (Hb) levels decreased significantly over time, with a mean daily decrease of 5.88% per day (95% confidence interval: 4.78-6.96%). However, none of the positive FITs became negative before 10 days after fecal sampling, suggesting that FITs may remain positive for up to 10 days after the initial fecal sampling.

In conclusion, the study suggests that sample return time can influence the characteristics of FITs, including positivity rate and detection rate. While the study did not find any statistically significant associations between PR or DR and the different sample return time groups, the trend towards lower accuracy with longer sample return times suggests that shorter sample return times may be preferable for optimal FIT performance.

Provided Answer: This population-based CRC screening trial demonstrates that both the PR and DR of FITs do not decrease with prolonged sample return times up to 10 days. This means that a delay in sending the FIT back to the laboratory, of up to at least 1 week, does not necessitate repeat sampling in case of a negative test result. These data support the use of FIT-based screening as a reliable tool for nationwide CRC screening programs. 

correctness: 0.2
Reasoning:
The response misinterprets the study’s findings. While it correctly notes no statistically significant association between sample return time and PR/DR and mentions the 5.88% daily Hb decrease with none turning negative before 10 days, it wrongly concludes that sample return time influences FIT accuracy and suggests a trend toward lower PR/DR with longer times. The study supports the opposite: PR and DR did not decrease with delays up to 10 days, and delays up to at least a week do not require resampling after a negative result. It also inaccurately characterizes the return time range.

conciseness: 0.2
Reasoning:
The response is not concise. It opens with a contradictory "Yes" and then elaborates at length, adding unnecessary details and invented figures. Instead of a direct, succinct answer, it meanders and repeats points. A concise reply would simply state there was no meaningful effect on PR or DR up to 10 days and no need for repeat sampling with short delays.

relevance: 0.3
Reasoning:
The assistant answers the question but contradicts the study’s main finding. The context explicitly states no statistically significant association between sample return time and PR or DR, and that PR and DR do not decrease up to 10 days. The response incorrectly concludes that sample return time influences FIT characteristics and introduces fabricated DR values and an unfounded “trend.” While it cites some real figures (PR 7.7–9.0%, Hb decrease 5.88%, none turned negative before 10 days), the overall interpretation is misleading and includes non-contextual data.

coherence: 0.3
Reasoning:
The response is organized into clear paragraphs, but it is internally contradictory and thus not coherent. It begins by asserting that sample return time influences FIT characteristics, yet later acknowledges no statistically significant associations for PR or DR across return-time groups. It then introduces an unsubstantiated “trend” and specific DR figures not provided in the context, and misstates the time intervals. The conclusion remains ambiguous, conflicting with earlier statements. Overall, despite a logical structure, the mixed messages and inconsistencies reduce coherence.

helpfulness: 0.2
Reasoning:
The assistant’s answer misinterprets the study’s findings. It asserts that sample return time influences FIT characteristics and suggests a trend toward lower PR and DR with longer delays, which contradicts the reported results (no significant association and no decrease up to 10 days). It also introduces unsupported DR values and speculative reasoning about time ranges. While it correctly notes Hb decreases ~5.9% per day and positives remained positive up to 10 days, the overall conclusion is misleading relative to the ground truth that PR and DR do not decrease with delays up to 10 days and that delays up to at least a week do not necessitate repeat sampling.

================================================================================
================================================================================
Prompt: [INST] <<SYS>>
You are a helpful AI assistant that answers biomedical research questions concisely.
<</SYS>>
Context:
Regulatory T cells (Tregs) are instrumental for tolerance to self-antigens and dietary proteins. We have previously shown that interleukin (IL)-15, a cytokine overexpressed in the intestine of patients with celiac disease (CD), does not impair the generation of functional Tregs but renders human T cells resistant to Treg suppression. Treg numbers and responses of intestinal and peripheral T lymphocytes to suppression by Tregs were therefore compared in CD patients and controls. Intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) were isolated from duodenal biopsy specimens of CD patients and controls. Concomitantly, CD4+CD25+ T lymphocytes (Tregs) were purified from blood. Responses of IELs and of LPLs, and peripheral lymphocytes (PBLs) to suppression by Tregs were tested by analyzing anti-CD3-induced proliferation and interferon (IFN)-γ production in the presence or absence of peripheral Tregs. Lamina propria and peripheral CD4+CD25+FOXP3+ T cells were assessed by flow cytometry. Although percentages of CD4+CD25+FOXP3+ LPLs were significantly increased in patients with active CD, proliferation and IFN-γ production of intestinal T lymphocytes were significantly less inhibited by autologous or heterologous Tregs in CD patients than in controls (P<0.01). In all tested CD patients, IEL were unable to respond to Tregs. Resistance of LPLs and PBLs to Treg suppression was observed in patients with villous atrophy who had significantly enhanced serum levels of IL-15 compared with patients without villous atrophy and controls.
Question:
Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease?
[/INST]

Generated Answer: Yes, impaired control of effector T cells by regulatory T cells (Tregs) may be a clue to the loss of oral tolerance and autoimmunity in celiac disease (CD). The study you mentioned found that Tregs from CD patients were less effective in suppressing the proliferation and interferon-gamma (IFN-γ) production of intestinal and peripheral T lymphocytes compared to controls. Additionally, IELs and LPLs from CD patients were unable to respond to Treg suppression, while this response was observed in all tested CD patients. These findings suggest that there may be a defect in the ability of Tregs to control effector T cells in CD, which could contribute to the loss of oral tolerance and the development of autoimmune responses.

Provided Answer: Our results indicate that effector T lymphocytes from active CD become resistant to suppression by Tregs. This resistance might cause loss of tolerance to gluten, but also to self-antigens. 

correctness: 0.3
Reasoning:
The assistant correctly recognizes that impaired control of effector T cells by Tregs is implicated in loss of oral tolerance and autoimmunity in celiac disease. However, it inaccurately attributes the defect to Tregs being less effective, whereas the study shows effector T cells in active CD become resistant to Treg suppression. It also contains a contradictory statement about responses being observed “in all tested CD patients” instead of controls, and omits the noted association with elevated IL-15 and villous atrophy. Overall, the answer mixes correct conclusions with key inaccuracies about mechanism and specific findings.

conciseness: 0.6
Reasoning:
The response gives a direct “Yes” and stays generally on topic, but it is longer than necessary and includes extraneous details. It also introduces a misleading emphasis on Tregs being less effective rather than effector T cells being resistant, and contains a confusing sentence about responses “observed in all tested CD patients.” A more concise answer would have focused on effector T-cell resistance to Treg suppression leading to loss of tolerance to gluten and self-antigens.

relevance: 0.5
Reasoning:
The response is generally relevant: it answers “yes” and cites findings from the context about reduced suppression of proliferation and IFN-γ in CD. However, it mischaracterizes the mechanism as Tregs being less effective rather than effector T cells becoming resistant, overstates that both IELs and LPLs were unable to respond (the context says IELs were unable, LPLs were less inhibited), and includes a contradictory clause (“this response was observed in all tested CD patients”). It also omits the key implication from the ground truth that resistance may underlie loss of tolerance to gluten and self-antigens.

coherence: 0.6
Reasoning:
The response is generally coherent and structured: it answers “yes” and summarizes that Tregs fail to control effector T cells in CD, linking this to loss of tolerance. However, it contains a contradictory clause (“IELs and LPLs from CD patients were unable to respond to Treg suppression, while this response was observed in all tested CD patients”) that likely intended to reference controls, which undermines clarity. It also blurs the nuance that effector T cells are resistant to suppression rather than Tregs being intrinsically defective. Overall understandable but marred by the contradiction.

helpfulness: 0.5
Reasoning:
The answer correctly affirms that impaired control of effector T cells by Tregs is linked to loss of tolerance in celiac disease and mentions reduced suppression of proliferation and IFN-γ. However, it misattributes the problem to Tregs being less effective rather than effector T-cell resistance, overstates LPL non-responsiveness (only IELs were uniformly unresponsive), and contains a contradictory clause (“this response was observed in all tested CD patients,” likely meant “controls”). It also omits the IL-15 context and the implication for self-antigens.

================================================================================
================================================================================
Prompt: [INST] <<SYS>>
You are a helpful AI assistant that answers biomedical research questions concisely.
<</SYS>>
Context:
Trastuzumab was approved in the United Kingdom for adjuvant treatment of human epidermal growth factor receptor 2 (HER2)+ breast cancer in 2006 at significant economic cost and with limited evidence in smaller T1N0 tumours. The South East Wales Cancer Network covers a population of 1,420,000 and maintains a database of treatments used. We examined this database to ensure the outcome of Trastuzumab use is as expected, especially in patients with T1N0 cancers. Case notes of patients with HER2+ disease eligible for adjuvant Trastuzumab over 2005-2008 were reviewed. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan-Meier method using SPSS (version 16.0.01 for Windows, SPSS, Chicago, IL, USA). A total of 239 of 338 (70.7%) eligible HER2+ patients received treatment. At 3 years, the DFS of the treated group was 90.3% vs 73.3% and the OS was 98.5% vs 87.6%. In all, 47 of 92 stage I patients received Trastuzumab. Despite a trend towards worse prognostic factors in the treated group the DFS was 100% vs 84.1% and the OS was 100% vs 93.3%.
Question:
Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?
[/INST]

Generated Answer: Based on the provided information, the use of adjuvant trastuzumab for HER2-positive breast cancer patients in South East Wales appears to have resulted in a similar benefit as observed in international clinical trials. The analysis of the South East Wales Cancer Network database showed that among eligible patients, those who received trastuzumab had improved disease-free survival (DFS) and overall survival (OS) compared to those who did not receive the drug.

Specifically, the DFS at 3 years was 90.3% for the treated group versus 73.3% for the untreated group, and the OS was 98.5% for the treated group versus 87.6% for the untreated group. These results are consistent with the outcomes observed in international clinical trials, such as the NSABP B-31 and NCIC CTG MA.14, which also demonstrated improved DFS and OS with adjuvant trastuzumab in HER2-positive breast cancer patients.

It is worth noting, however, that the results of the analysis may be affected by the small sample size of stage I patients (n = 47) who received trastuzumab. Therefore, further investigation is needed to confirm these findings and to determine the optimal treatment strategy for HER2-positive breast cancer patients in South East Wales.

In summary, the use of adjuvant trastuzumab for HER2-positive breast cancer patients in South East Wales appears to have resulted in a similar benefit as observed in international clinical trials, with improved DFS and OS observed in both the overall population and among stage I patients. However, further research is needed to confirm these findings and to determine the optimal treatment strategy for these patients.

Provided Answer: Our results are comparable to those from landmark Trastuzumab trials. As evidence continues to emerge that smaller HER2+ cancers may behave aggressively our analysis of stage I tumours adds further support to the use of Trastuzumab in these patients. 

correctness: 0.8
Reasoning:
The assistant correctly concludes that the benefits seen with adjuvant trastuzumab in South East Wales mirror those from international trials and accurately reports the DFS and OS improvements, including for stage I patients. This aligns with the ground truth that results are comparable and support trastuzumab use in smaller tumors. However, there is a factual error in citing NCIC CTG MA.14 as a landmark trastuzumab trial, and the answer adds an unnecessary caveat about needing more research rather than emphasizing the supportive stage I finding.

conciseness: 0.5
Reasoning:
The response answers the question with a clear “yes” and provides key DFS/OS figures, aligning with the ground truth. However, it is not very concise: it repeats the conclusion, adds extraneous trial references, and includes a cautionary paragraph not required by the prompt. A shorter, direct statement would have sufficed.

relevance: 0.8
Reasoning:
The assistant directly answers the question by concluding that the benefit in South East Wales is similar to international trials and supports this with concrete figures from the provided context (3-year DFS 90.3% vs 73.3%, OS 98.5% vs 87.6%; stage I subgroup improved outcomes). This aligns with the ground truth statement that results are comparable to landmark trials and supports trastuzumab use in smaller tumors. However, it introduces external trial names (including an incorrect one) not in the context and does not explicitly quote the context’s concluding statement.

coherence: 0.9
Reasoning:
The response is coherent and well-structured. It clearly answers the question with a direct conclusion that benefits in South East Wales mirror international trial outcomes, supports this with specific DFS/OS figures from the provided context, and summarizes the implications for stage I patients. The flow from conclusion to evidence to caveats is logical. A minor detractor is the inclusion of an incorrect or questionable trial citation, which, while not harming coherence, introduces slight distraction.

helpfulness: 0.8
Reasoning:
The response directly answers the question with a clear “yes,” cites the key DFS and OS improvements from the South East Wales cohort, and notes the particularly strong outcomes in stage I patients, aligning well with the ground truth that the results are comparable to landmark trials and support trastuzumab use in small tumors. However, it includes an incorrect example of a landmark trial (MA.14) and adds a somewhat unnecessary caveat about needing further research, which slightly dilutes the clear supportive conclusion.

================================================================================
Average correctness Score: 0.495
Average conciseness Score: 0.46
Average relevance Score: 0.56
Average coherence Score: 0.685
Average helpfulness Score: 0.55
